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Purpose: Advanced glycation end products of BSA (AGE-BSA) participate in the pathogenesis of diabetic vascular
disease.  However,  the  role  of  AGE-BSA  in  diabetic  retinopathy,  especially  in  retinal  neovascularization,  remains
incomplete. This study aimed to determine the contributions of AGE-BSA in the endothelial-to-mesenchymal transition
(EnMT) of cultured human and monkey endothelial cell lines and the mechanism that may be related with the transition.
Methods: Monkey choroid-retinal endothelial cells (RF/6A) and human umbilical vein endothelial cells (HUVEC) were
cultured in Dulbecco’s modified Eagle’s Medium (DMEM) and Ham’s F12 medium containing 200 mg/l AGE-BSA. The
expression  of  VE-cadherin,  β-catenin,  vimentin,  N-cadherin,  and  protein  kinase  B  (AKT2)  was  observed  by
immunocytochemistry and flow cytometry. Cell motility was determined by migration assays; the endothelial function of
the formatting tube was measured by tube formation assays, while the change in the polarity was measured using resistance
instruments.
Results: The characteristics of EnMT included loss of endothelial markers of VE-cadherin and β-catenin, which were
replaced by mesenchymal markers of vimentin and N-cadherin, enhanced migration and tube formation, and diminished
polarity.  AGE-BSA  contributed  to  upregulation  of  the  protein  expression  of  VE-cadherin  and  β-catenin  and
downregulation of protein expression of vimentin and N-cadherin, leading to enhanced migration and tube formation and
diminished polarity. During this process, expression of AKT2 was upregulated.
Conclusions: AGE-BSA can induce EnMT of cultured human and monkey endothelial cells. The signal pathway involving
AKT2 may play a role in this process.
In diabetic patients, reducing sugars, including glucose,
fructose, and aldotriose, can react nonenzymatically with the
amino groups of proteins to form reversible Schiff bases and
then  Amadori  products.  These  early  glycation  products
become irreversibly cross-linked heterogeneous fluorescent
derivatives termed “advanced glycation endproduct” (AGE)
[1] after further complex reactions, such as rearrangement,
dehydration, and condensation. The accumulation of AGEs in
vivo has been found to increase with age and at an accelerated
rate  in  diabetic  patients  [2].  AGEs  have  been  strongly
implicated in the initiation and acceleration of multiple-organ
damage  in  pathological  conditions  of  diabetic  etiology,
especially  the  pathogenesis  of  diabetic  microvascular  and
macrovascular  complications  [3,4],  and  non-diabetic
etiology, such as cardiovascular [5,6] and renal pathology of
aging  [5,7].  Tubular  cells  treated  with  AGE  have
myofibroblastic  phenotype  changes,  including  elongation,
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hypertrophy,  and  separation  from  neighboring  cells  [8].
Additionally,  tube  formation  and  migration  of  vascular
endothelial cells are dose-dependently stimulated by AGE
[9], which provide evidence that AGE can elicit angiogenesis
and  thereby  play  an  active  part  in  the  development  and
progression  of  diabetic  microangiopathy  [10].  This  may
account for the disabilities and high mortality rates in patients
with this disease [11].
Epithelial-to-mesenchymal  transition  (EMT)  was  first
described  in  the  three-dimensional  culture  of  corneal
epithelial cells in the laboratory of Hay in 1982 [12]. Since
then  many  attempts  have  been  made  to  define  this
phenomenon. These studies have shown that several types of
cells, including retinal pigment epithelial cells, glial cells,
fibroblasts, and cells with myofibroblast transformation, have
phenotypic changes and thus no longer resemble the normal
cell  populations  from  which  they  originated  [13].  This
transdifferentiation is a hallmark of EMT, by which epithelial
cells  lose  their  epithelial  phenotypes  and  acquire
mesenchymal,  fibroblast-like  properties,  show  reduced
intercellular adhesion, and show increased motility [1,12,14–
17]. Recently, some studies have found that, as a special part
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2669of epithelial cells, endothelial cells also can transdifferentiate
into  mesenchymal  cells  in  a  similar  way  which  is  called
endothelial-to-mesenchymal transition (EnMT).
Based on the above, we can suppose that endothelial cells
undergo EnMT during angiogenesis in diabetes. Since AGE
has important effects on the biologic properties of endothelial
cells, especially in subjects with diabetes, is this molecule, at
least in part, responsible for the EnMT of vascular endothelial
cells in diabetic complications? To address this question, we
investigated the effects of the interaction of monkey choroid-
retinal endothelial cells (RF/6A) and human umbilical vein
endothelial cells (HUVEC) with AGE-modified BSA (AGE-
BSA)  as  a  prototype  of  this  class  of  nonenzymically
glycosylated proteins. The mechanism was also detected by
measuring the changes of Akt2, which plays a role in human
cancer,  high-glucose-induced  EMT  [18],  and  leptin-
modulated EMT [19].
METHODS
BSA  and  AGE-BSA  were  purchased  from  BioVision
(Mountain  View,  CA).  Antihuman  β-catenin-fluorescein
monoclonal  antibody,  antihuman  Akt2-phycoerythrin
monoclonal antibody, and antihuman N-cadherin-fluorescein
monoclonal antibody were from R&D Systems (Minneapolis,
MN). Antihuman vimentin-fluorescein monoclonal antibody
was  from  Santa  Cruz  Biotechnology  (Santa  Cruz,  CA).
Antihuman VE-cadherin-phycoerythrin monoclonal antibody
was  from  eBioscience  (San  Diego,  CA).  Fluorescein-
conjugated AffiniPure goat antimouse immunoglobulin (IgG)
was  from  ZSGB-BIO  (Beijing,  China),  and  millicell  cell
culture inserts were from Millipore (Boston, MA). Matrigel
was  from  BD  Biosciences  (San  Jose,  CA).  The  monkey
choroid-retinal endothelial cell line RF/6A was obtained from
the cell bank of the Chinese Academy of Science (Shanghai,
China).  The  HUVEC  cell  line  was  from  American  Type
Culture Collection (ATCC number: CRL:1730; Rockville,
MD).
Cell  culture:  The  RF/6A  and  HUVEC  cell  lines  was
routinely cultured in a 1:1 mixture of Dulbecco’s modified
Eagle’s  medium  (DMEM;  Invitrogen,  Carlsbad,  CA)  and
Ham’s F12 medium (DF12; Invitrogen) supplemented with
10% (v/v) fetal bovine serum (FBS; Invitrogen), 100 U/ml
penicillin  (Invitrogen),  and  100  µg/ml  streptomycin
(Invitrogen). Cells were maintained at 37 °C, 5% CO2 in an
incubation cabinet. The culture medium was replaced twice
weekly. The fetal calf serum content was lowered to 2% (v/
v), and the glucose content was upgraded to 25 mmol/l when
the cells were exposed to AGE-modified or unmodified BSA
[20]. Cells were grown to confluence in 6-, 24-, or 48-well
plates and used within 24 h after confluence was achieved.
Cells were separated for subculture with trypsin (0.25%)/
EDTA  (EDTA;  Solarbio  Science  and  Technology
Corporation, Beijing, China; 0.02%).
Flow cytometry: RF/6A and HUVEC cells were seeded
onto a six-well plate. When 90% confluence was achieved,
cells were treated with AGE-BSA (200 mg/l) or BSA (200 mg/
l) for 24 h. Briefly, cells were separated with trypsin/EDTA
and washed twice in PBS at 200× g for 5 min before being
resuspended and fixed in 0.5 ml cold 4% paraformaldehyde
fixative and incubated at room temperature for 10 min. After
fixation the cells were washed twice in an isotonic phosphate
buffer solution (PBS, 154 mM NaCl, 16.8 mM Na2HPO4,
2.6 mM NaH2PO4,pH 7.4) supplemented with 0.5% BSA by
centrifuging at 200× g for 5 min, resuspended in 900 µl of
0.3% Triton X-100, incubated for 20 min at 4 °C, centrifuged
at 200× g for 5 min, and washed twice in PBS/BSA buffer.
After the second wash, approximately 200 µl of buffer was
left in the tube and cells were resuspended. The conjugated
antibodies of VE-cadherin, β-catenin, N-cadherin, Akt2, and
vimentin were added to the suspension before the cells were
incubated for 45 min at room temperature in the dark. After
washing  twice  using  PBS/BSA  buffer,  the  cells  were
resuspended in each tube with 200 µl of PBS for the final flow
cytometric analysis.
Immunocytochemistry: RF/6A and HUVEC cells were
seeded onto a 48-well plate. When confluence was achieved,
the cells were treated with AGE-BSA (200 mg/l) or BSA
(200 mg/l) for 24 h. Briefly, cells were rinsed in PBS twice
and fixed in 0.5 ml cold 4% paraformaldehyde for 20 min.
After rinsing in PBS three times, 5 min per time, the cells were
permeabilized with 0.3% Triton X-100 for 20 min and then
rinsed three times in PBS, 5 min per time. The plate was
incubated with primary antibody to VE-cadherin, β-catenin,
N-cadherin, Akt2, or vimentin overnight at 4 °C before being
rinsed and incubated with fluorescein-conjugated AffiniPure
goat antimouse IgG for 1 h at room temperature. Stained cells
were  visualized,  and  images  were  captured  using  a  laser
confocal microscope (Nikon/C1 Plus; Nikon, Tokyo, Japan).
Migration assays: RF/6A and HUVEC cells were seeded
onto a six-well plate, grown to confluent monolayers, and
treated with AGE-BSA (200 mg/l) or BSA (200 mg/l) for 24
h. A scratch wound was then inflicted on the monolayer with
a p20 pipette tip. The ability of the RF/6A and HUVEC cells
to close the wound space was used to assess the migratory
ability of the cells at 24 and 48 h after the scratch. Light
microscopic images were taken when the scratch was made
and at 24 h.
Transendothelial electrical resistance: RF/6A cells were
seeded onto millicell cell culture inserts (12 mm in diameter,
0.4 µm poly-carbonate-filter [PCF]) and mounted on a 24-well
plate for 10 days before treatment. Medium containing AGE-
BSA (200 mg/l) or BSA (200 mg/l) was added to the upper
(400 µl) and lower chambers (600 µl) of the millicell cell
culture inserts, while DF12 medium without drugs was added
to the control group. The cells were incubated at 37 °C, 5%
CO2  for  48  h,  and  the  medium  was  replaced  every  day.
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monolayers  was  measured  using  a  resistance  instrument
(Cat.No. MERS 00001, 0–1999Ω ; Millipore) immediately, at
24 h, and at 48 h after AGE-BSA or after BSA was mixed into
the medium. A group without cells was set as blank controls
[21]. Each group was measured three times at each time point,
and the average was used to calculate the TER by the formula
TER (Ω·cm2)=(the average of every group–the average of the
blank  control  group)×0.6  (the  undersurface  area  of  the
millicell cell culture inserts).
Tube formation assays: HUVEC cells were seeded on
matrigel-coated 96-well plates. The cells were treated with
medium  without  drugs,  medium  containing  AGE-BSA
(200 mg/l), or medium containing BSA (200 mg/l), and then
the cells were incubated at 37 °C, 5% CO2 for 6 h. Tube
formation  was  quantified  by  counting  the  number  of
connected  cells  in  randomly  selected  fields  at  100×
magnification.
Statistical analysis: One-way ANOVA (ANOVA) was
used for comparison between the AGE-BSA group and the
control  groups.  Paired-sample  t  test  was  used  for  the
comparison of cell polarity before and after treatment with
different  media.  A  p<0.05  was  considered  significantly
different.
RESULTS
Loss of endothelial markers and acquisition of mesenchymal
markers: In RF/6A cells, upregulation of the protein for N-
cadherin and vimentin (Figure 1C,D and Figure 2C,D) were
noted by immunocytochemistry and flow cytometry after 24-
h treatment. Moreover, by immunocytochemistry, N-cadherin
protein in the nucleus was significantly increased but that in
the cytoplasm decreased and even disappeared (Figure 2C).
The expression levels of VE-cadherin and β-catenin in the
cytoplasm decreased after 24-h treatment (Figure 1A,B and
Figure 2A,B), and the β-catenin level in the nucleus did not
show much change (Figure 2B). The total expression of VE-
cadherin was low not only in the treated group but also in the
control groups; total expression of VE-cadherin in the treated
group was lower (Figure 2A).
Similar to RF/6A cells, after treatment with AGE-BSA,
upregulation  of  the  protein  for  N-cadherin  and  vimentin
(Figure 1H,I and Figure 2H,I) in HUVEC cells were noted by
immunocytochemistry  and  flow  cytometry,  while  the
expression levels of VE-cadherin and β-catenin decreased
significantly (Figure 1F,G and Figure 2F,G). In contrast with
the RF/6A cells, the change in the expression level of proteins
was not different in the cytoplasm and the nucleus.
Enhanced migration after treatment: After treatment with a
different medium for 24 h, there were more cells in the scratch
inflicted on the monolayer in the AGE-BSA group compared
with the two control groups. The migration ability of the RF/
6A and HUVEC cells was enhanced significantly by AGE-
BSA (Figure 3).
Decreased  polarity  of  monkey  choroid-retinal  endothelial
cells: On the day 10 of the culture, there was no significant
difference in cell polarity between the AGE-BSA group and
the two control groups (p=0.961 and 0.873, respectively) and
between the two control groups (p=0.866). Compared with the
two  control  groups,  the  polarity  of  the  AGE-BSA  group
decreased  significantly  at  24  h  (p=0.027  and  0.031,
respectively) and 48 h (p=0.015 and 0.012, respectively) after
treatment with AGE-BSA. The difference in polarity between
the two control groups was not significant at the two time
points (p=0.715 and 0.969, respectively).
The polarity of cells decreased significantly at 24 h and
48  h  after  treatment  with  AGE-BSA  compared  with  that
before treatment (p=0.002 and 0.001, respectively), and the
difference between 24 h and 48 h was significant (p=0.011).
There was no difference in polarity between the two control
groups (Table 1).
Enhanced tube formation of human umbilical vein endothelial
cells:  After  treatment  with  different  medium  for  6  h,  the
number of tubes formatted by connected cells was more in the
AGE-BSA group than that in the two control groups. Tube
formation  ability  of  the  HUVEC  cells  was  enhanced
significantly by AGE-BSA (Figure 4).
Increased protein kinase B expression after treatment: There
was an obvious upregulation of the protein level of Akt2 in
RF/6A cells after treatment with AGE-BSA for 24 h. This
result  was  verified  by  flow  cytometry,  which  showed  a
significant difference between the AGE-BSA group and the
control  groups,  while  there  was  no  significant  difference
between  the  two  control  groups  (p=0.749;  Figure  1E  and
Figure 2E). The same result was found in HUVEC cells after
treatment with AGE-BSA for 24 h (Figure 1J and Figure 2J).
DISCUSSION
Microvessels are composed of two types of cells, endothelial
cells  and  pericytes,  and  have  been  known  to  show  both
functional  and  structural  abnormalities  during  prolonged
diabetic  exposure,  resulting  in  deleterious  effects  on  the
organs that they supply [22–24]. It was reported that AGE
exerts  a  growth  inhibitory  effect  and  a  cell  type-specific
immediate  toxicity  on  pericytes  through  interactions  with
their receptor for AGE and leads to pericyte loss. The AGE-
induced decrease in pericyte number would indirectly cause
angiogenesis [25,26].
AGEs in circulation and on the subendothelium interact
directly  with  endothelial  cells  through  a  specific  binding
system.  The  functional  consequences  of  AGE-endothelial
interactions include decreasing the expression of VE-cadherin
[27] and increasing the expression of the vimentin, α-smooth
muscle actin, and matrix proteins [8], leading to the disruption
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2671Figure 1. Flow cytometry was used to illustrate altered expression of VE-cadherin, β-catenin, vimentin, N-cadherin, and protein kinase B
(AKT2) in monkey choroid-retinal endothelial cells (RF/6A) and human umbilical vein endothelial cells (HUVEC) after the treatment with
advanced glycation end products of BSA (AGE-BSA; 200 mg/l) for 24 h. For RF/6A cells, there were decreased expression of markers of
endothelial cells, VE-cadherin (A) and β-catenin (B), and increased expression of markers of mesenchymal cells, N-cadherin (C) and vimentin
(D). Similar to the RF/6A cells, the protein expression of VE-cadherin (F) and β-catenin (G) in the HUVEC cells was downregulated, and
the expression of N-cadherin (H) and vimentin (I) in the HUVEC cells was upregulated. At the same time, the expression of Akt2 in the both
cells increased (E, J). *p<0.05, **p<0.01, ***p<0.001.
Molecular Vision 2010; 16:2669-2679 <http://www.molvis.org/molvis/v16/a286> © 2010 Molecular Vision
2672of  the  vascular  endothelial  cadherin  complex  of  the
endothelial cells and increasing vascular permeability [6].
Some investigations have demonstrated that sustained
hyperglycation results in a gradual AGE accumulation within
retinal  cellular  and  extracellular  structures,  including
basement  membrane,  endothelium,  pericytes,  and  smooth
muscle cells of diabetic rats. AGE epitopes occur first in the
retinal vascular basement membrane of newly diabetic rats.
AGE formation has been suggested as a plausible factor for
the irreversible components of diabetic complication [23,28].
In this study, we examined the effects of AGE-BSA on RF/
6A and the HUVEC cell line and showed a loss of endothelial
markers and a gain of mesenchymal markers. At the same
time, cells had increased motility, enhanced tube formation,
and  decreased  polarity.  EnMT  of  endothelial  cells  is
associated  with  decreased  expression  of  endothelial  cell
markers, which is in conjunction with increased expression of
mesenchymal cell markers, N-cadherin, and vimentin [29–
33]. Endothelial cells occupy a central anatomic position in
the microvessels. Therefore, AGE-induced endothelial cell
changes may contribute in part to diabetic neovascularization,
which is an important cause leading to diabetic complication.
Figure 2. Immunocytochemistry was used to illustrate altered expression of VE-cadherin, β-catenin, vimentin, N-cadherin and protein kinase
B (AKT2) in monkey choroid-retinal endothelial cells (RF/6A) and human umbilical vein endothelial cells (HUVEC) after the treatment by
advanced glycation end products of BSA (AGE-BSA; 200 mg/l) for 24 h. For RF/6A cells, there were decreased expression of markers of
endothelial cells, VE-cadherin (A) and β-catenin (B), and increased expression of markers of mesenchymal cells, N-cadherin (C) and vimentin
(D). Similar to the RF/6A cells, the protein expression of VE-cadherin (F) and β-catenin (G) in the HUVEC cells was downregulated, and
the expression of N-cadherin (H) and vimentin (I) in the HUVEC cells was upregulated. At the same time, the expression of Akt2 in the both
cells increased (E, J). Additionally, in the RF/6A cells, the decreased part of β-catenin was mainly in the cytoplasm, while the protein expressed
in the nucleus changed little (B); after treatment with AGE-BSA, N-cadherin expression was upregulated in the nucleus and downregulated
in the intracytoplasm (D). In the HUVEC cells, there were no such phenomena.
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2673VE-cadherin,  as  an  integral  membrane  glycoprotein
expressed exclusively in endothelial cells [34–36], clusters at
endothelial cell junctions, mediates cell adhesion in a calcium-
dependent manner, inhibits cell proliferation, and decreases
cell  permeability  and  migration  when  overexpressed  in
various cell types [37–39]. In addition, VE-cadherin functions
as a plasma membrane attachment site for the cytoskeleton
through its interactions with the cytoplasmic protein β-catenin
[40],  which  is  an  armadillo  family  member  that  binds
intracellularly to the VE-cadherin cytoplasmic domain and
also a structural protein involved in cell–cell adhesion [41].
The  VE-cadherin–β-catenin  complex  is  essential  in
endothelial cells for normal vascular patterning [42,43]. It is
a target of permeability increasing agents. The dissociation of
this  complex  leads  to  the  reduction  of  cell  adhesion  and
increase  of  cell  permeability  [44].  Previous  studies  have
shown  that  the  catenin–cadherin  complex  is  required  to
maintain  the  mammary  gland  architecture  and  influences
polarity,  cell  fate,  and  motility  of  epithelial  cells  [45].
Perturbation of the β-catenin–E-cadherin complex can result
in the nuclear localization of β-catenin, which is associated
with  increased  vimentin  and  vascular  endothelial  growth
factor  expression  along  with  a  potentially  more  invasive
phenotype [46]. This phenomenon was also observed in RF/
6A but not HUVEC cells. In RF/6A cells, the decreased part
of  β-catenins  was  almost  in  the  cytoplasm,  while  the
expression in the nucleus changed invisibly, which is similar
to the findings of Mironchik et al. [32]. On the other hand, the
formation  of  AGEs  has  been  strongly  implicated  in  the
endothelial dysfunction associated with microvascular and
macrovascular complications that accompany diabetes and
normal aging by altering the structural of endothelial junction
organization [4,20]. In the current study, exposure of RF/6A
and HUVEC cells to AGE-BSA for 24 h induced a decrease
in the amount of VE-cadherin and the major component of the
VE-cadherin  complex  that  were  linked  directly  to  the
Figure 3. Advanced glycation end products of BSA (AGE-BSA) induced enhanced migration in transdifferentiated monkey choroid-retinal
endothelial cells (RF/6A) and human umbilical vein endothelial cells (HUVEC). Light microscopic images shows the increased migratory
ability of cells after 24 h of treatment with AGE-BSA. The images were taken at 24 h after the scratch was applied. The migratory ability of
the transdifferentiated cells was most obvious in the cells treated with AGE-BSA after scratch injury. ***p<0.001.
TABLE 1. THE TER OF THE THREE GROUP AT DIFFERENT TIME AFTER THE TREATMENT (Ω·CM2)
Groups n Before treatment 24 h after treatment 48 h after treatment
Norm 4 37.84±3.79 36.79±3.00 36.68±4.18
AGE-BSA 4 37.95±2.21 31.31±2.36** 28.54±2.45**
BSA 4 38.29±3.40 37.73±3.91 36.56±3.75
        Paired-sample t-test was used for comparison of cell polarity before and after treatment with different media at different times,
        which revealed a significant decrease of cell polarity after 24-h and 48-h AGE-BSA treatment, but there was no significant
        difference between the normal and BSA groups. **p<0.01.
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2674cytoplasmic tail of VE-cadherin and β-catenins. This, in turn,
could induce perturbations to properties of the endothelium
and thereby contribute to vascular dysfunction. This finding
is in agreement with the idea that AGE-BSA greatly alters the
organization  of  the  endothelial  VE-cadherin  complex  of
HUVEC [20].
One study has found that, after withdrawal of AGE-BSA,
the  barrier  properties  caused  by  AGE-BSA  returned  to
baseline,  with  a  concomitant  increase  in  the  VE-cadherin
complex content. This suggests that AGEs must be constantly
present to exert the observed effects. This is in accordance
with AGE physiology, as AGE proteins accumulate in the
vasculature with aging and at an accelerated rate in diabetes.
The effects exerted by AGEs should be related to their chronic
presence in the diabetic milieu [20].
Normal endothelial cells express only a small amount of
N-cadherin and vimentin. Vimentin is the major intermediate
filament of mesenchymal cells and has viscoelastic properties
that allow it to stabilize cell structure in migration. Elevated
expression of vimentin contributes to the biologic properties
of cells, including enhanced proliferation and motility [47],
which  are  the  biologic  properties  of  mesenchymal  cells.
Decreases in the levels of cellular cadherins may affect other
cadherins presenting in endothelial cells, namely neural (N)-
cadherin. This is a classical cadherin presenting in significant
amounts in endothelial cells [48]. It interacts with catenins and
the actin cytoskeleton to promote homotypic endothelial cell–
cell adhesion. In endothelial cells, N-cadherin is not located
at cell–cell contacts but remains diffuse on the cell membrane.
VE-cadherin  appears  to  play  a  predominant  role  over  N-
cadherin  in  promoting  homotypic  endothelial  cell–cell
adhesion and barrier properties, while N-cadherin may be
involved in the interaction of endothelial cells with other cell
types in the vasculature [49]. In our study, after exposure to
AGE-BSA for 24 h, N-cadherin expression was evidently
upregulated  in  both  cell  lines.  It  is  interesting  that  the
increased part of N-cadherin in RF/6A cells was limited in the
nucleus, while the expression in the cytoplasm decreased and
even disappeared, which was not found in HUVEC cells. In
epithelial  malignancies,  concurrent  with  the  loss  of  E-
cadherin expression, gain of N-cadherin expression has been
shown to be important in the regulation of cell migration,
invasion,  and  survival  [50–52].  In  addition,  aberrant  N-
cadherin  expression  in  the  nucleus  is  required  for  cell
migration during transforming TGFβ1-stimulated epithelial-
to-mesenchymal transformation [53]. In this study, we noticed
Figure 4. The tube formation ability of the human umbilical vein endothelial cells (HUVEC) was enhanced significantly by advanced glycation
end products of BSA (AGE-BSA). After treatment with different media for 6 h, the number of the tube formatted by connected cells in the
AGE-BSA group was larger than that in the two control groups. The tube formation ability was enhanced evidently after AGE-BSA treatment.
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2675different  changes  in  the  two  cell  lines,  and  further
investigations are needed to explain this difference.
It should be noted, however, that the cells used in this
study were cell lines, not primary endothelial cells. In general,
endothelial  cell  lines  may  have  already  acquired
mesenchymal characteristics, and the degree of mesenchymal
phenotype expressed is different from one cell line to another.
It is therefore not justified to expect that expression of the
same type of endothelial molecules in various endothelial cell
lines or expression of the same mesenchymal molecules in
various mesenchymal cell lines will be comparable [54]. In
fact, RF/6A is considered to be a typical normal endothelial
cell line, which expresses a low level of VE-cadherin but a
high  level  of  the  mesenchymal  markers,  N-cadherin  and
vimentin.  In  this  study,  the  expression  of  the  endothelial
molecules  was  downregulated,  while  the  mesenchymal
molecules were upregulated further after treatment with AGE-
BSA. Moreover, our results were obtained at only 24 h after
treatment  when  the  contact  among  cells  was  perhaps
insufficient. It is not surprising that the protein associated with
contact had a low expression.
At the cellular level, EnMT includes two distinct steps:
decreased  intercellular  adhesion  (to  dissociate  from  the
endothelial cellular sheets) and increased cell motility (to
migrate  into  connective  tissues).  Endothelial  cells  are
characterized by two major histological findings [55]. First,
they have the ability to form barriers between the two tissue
compartments that the endothelium separates. Second, the
plasma membrane of the cell is intrinsically polarized into
apical  and  basolateral  domains.  Endothelial  tightness  is
maintained by formation of specialized structures known as
tight  junctions.  Apart  from  restricting  the  paracellular
movement of molecules and ions across the endothelial sheet,
tight junctions also have a role in the maintenance of the
apical/basolateral  polarity  [56,57].  By  decreasing  VE-
cadherin  in  the  membrane  domain  facing  the  apical
compartment  and  increasing  apical  accessibility  via  tight
junctions, AGE-BSA decreases the degree of polarization in
RF/6A  and  HUVEC  cells  and  decreases  intercellular
adhesion.  Enhanced  migration  is  the  other  important
characteristic of EnMT. During EMT, cellular transformation
drives epithelial remodeling by converting cohesive, stable,
epithelial layers into individual, motile, mesenchymal cells,
allowing the efficient migration of cohesive epithelium that
maintains  internal  organization  [58].  In  our  study,  after
treatment with AGE-BSA for 24 h, the migration of RF/6A
and HUVEC cells was enhanced, which was associated with
the disruption of the VE-cadherin–β-catenin complex and the
gain of N-cadherin and vimentin [59]. During this process,
cellular  transformation  resulted  in  a  loss  of  apical  basal
polarity, followed by a shift in cytoskeletal dynamics toward
the mesenchymal phenotype. This allowed the cells to move
freely [18], leading to the dysfunction of the microvessels.
From the tube formation study of HUVEC cells, we also found
that the decreased polarity and increased motility resulted in
the enhanced ability of tube formation, which could facilitate
the formation of neovascularization in vivo. This result was
consistent  with  the  demonstration  that  AGE-BSA
significantly increased cell migration and tube formation in
retinal endothelial cells [60].
The mechanism of EMT has been investigated by many
researchers, but EnMT has only had limited investigation. In
the present study, we noticed that after treatment with AGE-
BSA,  the  Akt2  expression  in  RF/6A  cells  was  visibly
upregulated.  Previous  studies  revealed  that  during  EMT,
engagement of E-cadherin in homophylic calcium-dependent
cell–cell  interactions  results  in  rapid  PI3K-dependent
activation  of  Akt,  indicating  that  E-cadherin  can  initiate
outside-in  signal  transducing  pathways  that  regulate  the
activity of PI3K and Akt [17,61]. An activated PI3K/Akt
pathway is well documented for various human malignancies,
sometimes correlates with an aggressive phenotype [62], and
plays a central role in EMT [63–66]. The upregulation of the
Akt-involved signaling pathway in this study participated, at
least partly, in AGE-BSA-induced EnMT, which may play an
important  role  in  the  transition.  It  was  reported  that  the
expression of Akt in mesenchymal cells signifies a potential
role in maintenance of the mesenchymal phenotype after EMT
or participation in invasion-associated cellular activities [67].
In  contrast,  with  activation  of  the  Akt-involved  pathway
during  the  EMT,  Song  et  al.  provided  evidence  that  N-
cadherin acts as a negative regulator of cell proliferation and
survival  in  osteoblasts  via  interaction  with  LRP5  and
attenuation of Wnt, ERK, and PI3K/Akt signaling pathways
[61].
In conclusion, AGE-BSA can induce the endothelial-to-
mesenchymal transition of RF/6A and HUVEC cells. The
signal pathway involves AKT2, which may play a certain role
in this process. Further investigations are required to discuss
the inner mechanism of AGE-BSA-induced EnMT.
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